[go: up one dir, main page]

AR119199A1 - Compuestos para el tratamiento de trastornos neuromusculares - Google Patents

Compuestos para el tratamiento de trastornos neuromusculares

Info

Publication number
AR119199A1
AR119199A1 ARP200101736A ARP200101736A AR119199A1 AR 119199 A1 AR119199 A1 AR 119199A1 AR P200101736 A ARP200101736 A AR P200101736A AR P200101736 A ARP200101736 A AR P200101736A AR 119199 A1 AR119199 A1 AR 119199A1
Authority
AR
Argentina
Prior art keywords
substituents
optionally substituted
different
cycloalkyl
alkyl
Prior art date
Application number
ARP200101736A
Other languages
English (en)
Inventor
Lars J S Knutsen
Nicholas Kelly
Skov Martin Brandhj
Anders Riisager
Neerja Saraswat
Original Assignee
Nmd Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nmd Pharma As filed Critical Nmd Pharma As
Publication of AR119199A1 publication Critical patent/AR119199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/295—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with inorganic bases, e.g. by alkali fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/287—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), en donde: R¹ está seleccionado del grupo que consiste en C₁₋₂ alquilo, C₂ alquenilo, C₂ alquinilo, CN, CF₃, NO₂, F, Cl, Br, y I; R² está seleccionado del grupo que consiste en C₁₋₅ alquilo opcionalmente sustituido con uno o más sustituyentes R⁶, idénticos o diferentes, C₂₋₅ alquenilo opcionalmente sustituido con uno o más sustituyentes R⁶, idénticos o diferentes, C₂₋₅ alquinilo opcionalmente sustituido con uno o más sustituyentes R⁶, idénticos o diferentes, C₃₋₅ cicloalquilo sustituido opcionalmente con uno o más sustituyentes R⁶, idénticos o diferentes, fenilo sustituido opcionalmente con uno o más sustituyentes R⁹, idénticos o diferentes, y heterociclo aromático de 5 - 6 miembros sustituido opcionalmente con uno o más sustituyentes R⁷, idénticos o diferentes; R³ está seleccionado del grupo que consiste en deuterio, Cl y F; R⁴ está seleccionado del grupo que consiste en H, deuterio, C₁₋₅ alquilo, C₂₋₅ alquenilo, C₂₋₅ alquinilo, y C₃₋₅ cicloalquilo, cada uno de los cuales puede estar sustituido opcionalmente con uno o más sustituyentes R⁷, idénticos o diferentes; R⁵ está seleccionado del grupo que consiste en H, C₁₋₅ alquilo sustituido opcionalmente con uno o más sustituyentes R⁸, idénticos o diferentes, C₂₋₅ alquenilo sustituido opcionalmente con uno o más sustituyentes R⁸, idénticos o diferentes, C₂₋₅ alquinilo sustituido opcionalmente con uno o más sustituyentes R⁸, idénticos o diferentes, C₃₋₆ cicloalquilo sustituido opcionalmente con uno o más sustituyentes R⁸, idénticos o diferentes, fenilo sustituido opcionalmente con uno o más sustituyentes R⁹, idénticos o diferentes, y bencilo sustituido opcionalmente con uno o más sustituyentes R⁹, idénticos o diferentes; R⁶ está independientemente seleccionado del grupo que consiste en deuterio, F, -CN, -O-C₁₋₅ alquilo, -O-C₃₋₅ cicloalquilo, -S-C₁₋₅ alquilo, y -S-C₃₋₅ cicloalquilo, en donde -O-C₁₋₅ alquilo, -O-C₃₋₅ cicloalquilo, -S-C₁₋₅ alquilo, y -S-C₃₋₅ cicloalquilo pueden estar opcionalmente sustituidos con uno o más sustituyentes R⁸, idénticos o diferentes; R⁷ está independientemente seleccionado del grupo que consiste en deuterio, F, Cl, -CN, C₃₋₅ cicloalquilo, -O-C₁₋₅ alquilo, -O-C₃₋₅ cicloalquilo, -S-C₁₋₅ alquilo, y -S-C₃₋₅ cicloalquilo, en donde C₃₋₅ cicloalquilo, -O-C₁₋₅ alquilo, -O-C₃₋₅ cicloalquilo, -S-C₁₋₅ alquilo, y -S-C₃₋₅ cicloalquilo pueden estar opcionalmente sustituidos con uno o más sustituyentes R⁸, idénticos o diferentes; R⁸ está independientemente seleccionado del grupo que consiste en deuterio y F; R⁹ está independientemente seleccionado del grupo que consiste en deuterio, metoxi, nitro, ciano, Cl, Br, I, y F; X es un enlace o está seleccionado del grupo que consiste en -O-, -S-, -CH₂-, -CHR⁶-, y -C(R⁶)₂-; y n es un entero 0, 1, 2, ó 3; o una sal, hidrato, polimorfo, tautómero, o solvato farmacéuticamente aceptables del mismo.
ARP200101736A 2019-06-19 2020-06-19 Compuestos para el tratamiento de trastornos neuromusculares AR119199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181270 2019-06-19

Publications (1)

Publication Number Publication Date
AR119199A1 true AR119199A1 (es) 2021-12-01

Family

ID=66999610

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101736A AR119199A1 (es) 2019-06-19 2020-06-19 Compuestos para el tratamiento de trastornos neuromusculares

Country Status (21)

Country Link
US (1) US12415771B2 (es)
EP (1) EP3986852B1 (es)
JP (1) JP7662196B2 (es)
KR (1) KR102822753B1 (es)
CN (1) CN114008012B (es)
AR (1) AR119199A1 (es)
AU (1) AU2020298088B2 (es)
BR (1) BR112021025637A2 (es)
CA (1) CA3138332A1 (es)
CL (1) CL2021003318A1 (es)
CO (1) CO2021016931A2 (es)
IL (1) IL288234B2 (es)
MA (1) MA56501A (es)
MX (1) MX2021013508A (es)
PE (1) PE20220391A1 (es)
PH (1) PH12021552771A1 (es)
SA (1) SA521431094B1 (es)
SG (1) SG11202112250QA (es)
TW (1) TW202114977A (es)
WO (1) WO2020254559A1 (es)
ZA (1) ZA202108083B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260007625A1 (en) 2022-09-15 2026-01-08 Nmd Pharma A/S Compounds for the Treatment of Neuromuscular Disorders
AU2024311729A1 (en) 2023-06-20 2025-11-27 Nmd Pharma A/S Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3709926A (en) * 1971-02-01 1973-01-09 Dow Chemical Co Substituted phenoxy-alkanoic acids and derivatives thereof
IL111613A0 (en) * 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
US6558414B2 (en) * 1999-02-02 2003-05-06 Impra, Inc. Partial encapsulation of stents using strips and bands
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
UY29223A1 (es) 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062678A1 (en) 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
RU2745065C2 (ru) 2015-06-15 2021-03-18 ЭнЭмДи ФАРМА A/C Соединения для применения для лечения нервно-мышечных расстройств
TWI794369B (zh) 2017-12-14 2023-03-01 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
TW201927738A (zh) 2017-12-14 2019-07-16 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
US10385028B2 (en) * 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US20190183812A1 (en) 2017-12-14 2019-06-20 Nmd Pharma A/S Compounds For The Treatment Of Neuromuscular Disorders
SG11202106399XA (en) 2019-01-04 2021-07-29 Praxis Biotech LLC Inhibitors of fibroblast activation protein
WO2020257487A1 (en) 2019-06-19 2020-12-24 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
CN119039288A (zh) 2019-06-19 2024-11-29 Viiv保健英国第五有限公司 作为人类免疫缺陷病毒复制抑制剂的吡啶并[2,3-d]嘧啶衍生物

Also Published As

Publication number Publication date
KR102822753B1 (ko) 2025-06-20
SA521431094B1 (ar) 2024-04-24
JP7662196B2 (ja) 2025-04-15
ZA202108083B (en) 2023-05-31
IL288234B1 (en) 2024-10-01
MX2021013508A (es) 2021-12-10
MA56501A (fr) 2022-04-27
CN114008012A (zh) 2022-02-01
BR112021025637A2 (pt) 2022-02-01
EP3986852A1 (en) 2022-04-27
TW202114977A (zh) 2021-04-16
AU2020298088B2 (en) 2025-08-14
SG11202112250QA (en) 2021-12-30
WO2020254559A1 (en) 2020-12-24
IL288234A (en) 2022-01-01
AU2020298088A1 (en) 2021-11-18
CN114008012B (zh) 2025-02-25
PH12021552771A1 (en) 2022-10-17
PE20220391A1 (es) 2022-03-18
CO2021016931A2 (es) 2022-01-17
US20220388938A1 (en) 2022-12-08
EP3986852B1 (en) 2024-10-16
EP3986852C0 (en) 2024-10-16
KR20220023337A (ko) 2022-03-02
JP2022538541A (ja) 2022-09-05
US12415771B2 (en) 2025-09-16
IL288234B2 (en) 2025-02-01
CL2021003318A1 (es) 2022-09-02
CA3138332A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR093580A1 (es) Inhibidores bmi-1 de pirimidina sustituidos
AR088748A1 (es) Macrociclos como inhibidores del factor xia
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR104555A1 (es) SULFONAS TRICÍCLICAS COMO MODULARES DE RORg
EA201600403A1 (ru) N-ацилиминогетероциклические соединения
AR100714A1 (es) Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
AR115965A1 (es) Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática
AR108076A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR117037A1 (es) Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias
AR109651A1 (es) Compuestos de piridina y pirazina como inhibidores de ripk2
AR119199A1 (es) Compuestos para el tratamiento de trastornos neuromusculares
AR119198A1 (es) Proceso para la preparación de inhibidores del canal de cloruro cic-1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal